食品伙伴網(wǎng)訊 據(jù)美國(guó)食品藥品管理局(FDA)消息,11月18日美國(guó)食品藥品管理局(FDA)發(fā)布嬰配食品標(biāo)識(shí)當(dāng)中聲稱所需科學(xué)依據(jù)的指南草案,并就此征求意見(jiàn),截至日期為2017年2月21日。
嬰兒奶粉標(biāo)簽與標(biāo)識(shí)“結(jié)構(gòu)/功能”聲稱是指產(chǎn)品的效果或者組分對(duì)正常結(jié)構(gòu)或者身體功能的效果。例如奶粉標(biāo)簽上面的“助消化”。
部分原文報(bào)道如下:
The U.S. Food and Drug Administration has issued draft guidance for industry to help infant formula manufacturers making structure/function claims comply with the requirement that all claims in infant formula labels and labeling be truthful and not misleading.
“Structure/function” claims are statements made about the effects of a product or its constituent on the normal structure or function of the body. An example of a structure/function claim in infant formula labeling is a statement that the formula “supports digestion.”
In the draft guidance, “Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,” the FDA describes its recommendations for the type and quality of scientific evidence that is appropriate to substantiate (i.e., support) structure/function claims made about an infant formula by the product's manufacturers or distributors. The draft guidance provides recommendations with respect to all infant formulas, including formulas marketed for use by infants who have inborn errors of metabolism or low birth weight, or who otherwise have unusual medical or dietary problems.
原文鏈接:http://www.fda.gov/food/newsevents/constituentupdates/ucm514389.htm